Skip to content
Inciteful Med

FNAIT and Future Pregnancies: Risk, Screening, and Treatment

Last updated:

If you have had a baby with FNAIT, future pregnancies can be proactively managed to protect your next child. Doctors use paternal genetic testing and non-invasive prenatal testing (NIPT) to assess risk, followed by maternal IVIG infusions during pregnancy to prevent dangerous fetal bleeding.

Key Takeaways

  • • Paternal genetic testing determines if a future baby has a 50% or 100% chance of being at risk for FNAIT.
  • • Non-Invasive Prenatal Testing (NIPT) can safely check the baby's platelet type using the mother's blood as early as 10 weeks.
  • • Maternal IVIG infusions are the gold standard treatment to protect the baby's platelets during an at-risk pregnancy.
  • • The timing of when to start IVIG treatment depends on the severity of the mother's previous FNAIT pregnancy.
  • • Invasive procedures like fetal blood sampling are no longer standard of care due to significant bleeding risks.

When you have already experienced the shock of an FNAIT diagnosis, planning for a future pregnancy can feel daunting. However, because the “surprise” element is gone, your medical team can take a proactive, non-invasive approach to protect your next baby [1][2].

Assessing Your Risk

The risk of FNAIT recurring in a subsequent pregnancy is high, and the severity often equals or exceeds that of the previous pregnancy [3]. The first step in family planning is paternal genotyping to check the father’s “zygosity” (genetic makeup) [4].

  • Homozygous: If the father has two copies of the “mismatched” antigen gene, 100% of his children with the same mother will be at risk [4][5].
  • Heterozygous: If he has only one copy, there is a 50% chance that any given pregnancy will be affected and a 50% chance the baby will be compatible with the mother and completely unaffected [4][6].

A New Era of Testing: NIPT

In the past, doctors often used invasive tests like amniocentesis (inserting a needle into the uterus) to check a baby’s HPA status. Today, Non-Invasive Prenatal Testing (NIPT) allows doctors to determine the baby’s HPA genotype using a simple blood draw from the mother [6][7].

  • How it works: Tiny fragments of the baby’s DNA (cell-free fetal DNA) circulate in the mother’s blood [6].
  • Timing: This test can often be performed as early as 10 to 12 weeks of pregnancy [8][9].
  • Impact: If the NIPT shows the baby is HPA-compatible with the mother, no further treatment or specialized monitoring is needed for that pregnancy [4][6].

Antenatal Treatment: Proactive Protection

If the baby is at risk, the goal of treatment during pregnancy is to prevent the baby’s platelets from dropping to dangerous levels. The standard of care is now non-invasive, meaning doctors treat the mother rather than the baby directly [10][11].

Intravenous Immunoglobulin (IVIG) is the “gold standard” treatment [12][13]. It is typically given to the mother as a weekly infusion. While highly effective, it is important to know that this treatment requires a significant time commitment and can cause physical side effects for the mother, such as intense headaches, fatigue, and nausea [14][12].

The timing of when to start depends on risk stratification—a fancy way of saying how severe the previous case was [4][15]:

  • High-Risk: If a previous child had an intracranial hemorrhage (ICH) or severe bleeding, treatment may start as early as 12 to 18 weeks [13][4].
  • Standard-Risk: If the previous child had low platelets but no ICH, treatment typically begins between 20 and 28 weeks [13][12].

In some high-risk cases, doctors may add oral corticosteroids to the IVIG treatment, though the most critical component remains the IVIG infusions [4][10].

Why We No Longer Sample Fetal Blood

Years ago, it was common for doctors to perform “fetal blood sampling” (FBS) to check the baby’s platelet count while still in the womb. However, because FBS carries a significant risk of causing the very bleeding it aims to prevent, it is no longer the standard of care [10][7]. Modern management relies on the high success rate of maternal IVIG therapy and NIPT to keep both the mother and baby safe without invasive procedures [10][11].

Frequently Asked Questions

What is the risk of FNAIT recurring in my next pregnancy?
The risk depends on the father's genetics. If he is homozygous for the mismatched antigen gene, there is a 100% chance the baby will be at risk. If he is heterozygous, there is a 50% chance the baby will be affected.
Can doctors test my baby for FNAIT without an invasive procedure?
Yes. Non-Invasive Prenatal Testing (NIPT) can determine the baby's genetic status using a simple blood draw from the mother. This test can safely be performed as early as 10 to 12 weeks of pregnancy.
How is FNAIT treated during pregnancy?
The standard of care is Intravenous Immunoglobulin (IVIG), which is given as a weekly infusion to the mother. This treats the baby indirectly and avoids the risks associated with invasive fetal procedures.
When does IVIG treatment start for a pregnancy at risk of FNAIT?
The timing depends on the severity of your previous pregnancy. High-risk cases often start IVIG between 12 and 18 weeks, while standard-risk cases typically begin treatment between 20 and 28 weeks.
Why do doctors no longer perform fetal blood sampling for FNAIT?
Fetal blood sampling carries a significant risk of causing the exact type of severe bleeding it is trying to prevent. Modern medicine now relies on highly effective maternal IVIG therapy and non-invasive NIPT to safely manage the pregnancy.

Questions for Your Doctor

  • • Is the father homozygous or heterozygous for the Human Platelet Antigen (HPA)?
  • • Based on our previous experience, will my next pregnancy be classified as 'standard-risk' or 'high-risk'?
  • • Can we use Non-Invasive Prenatal Testing (NIPT) to check the baby's HPA status starting at 10-12 weeks?
  • • What is the specific plan for the timing and dosage of weekly IVIG treatments?
  • • Will corticosteroids be added to my treatment plan, and what are the potential side effects for me?

Questions for You

  • • Have I discussed my previous FNAIT experience with a Maternal-Fetal Medicine (MFM) specialist?
  • • How do I feel about the prospect of weekly hospital visits for IVIG infusions during a future pregnancy?
  • • Do I have a copy of the diagnostic reports from my first child's birth to share with new doctors?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    From concept to practice: Screening for fetal and neonatal alloimmune thrombocytopenia (FNAIT).

    Pothof R, de Vos TW, Lopriore E, et al.

    Best practice & research. Clinical obstetrics & gynaecology 2025; (103()):102683 doi:10.1016/j.bpobgyn.2025.102683.

    PMID: 41161115
  2. 2

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT): From reactive transfusion to proactive prevention.

    Liu J, Liang X, Yu S

    European journal of obstetrics, gynecology, and reproductive biology 2026; (321()):115046 doi:10.1016/j.ejogrb.2026.115046.

    PMID: 41791326
  3. 3

    Clinical and laboratory predictors of fetal and neonatal alloimmune thrombocytopenia.

    Matusiak K, Patriquin CJ, Deniz S, et al.

    Transfusion 2022; (62(11)):2213-2222 doi:10.1111/trf.17144.

    PMID: 36239096
  4. 4

    Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach.

    Lieberman L, Greinacher A, Murphy MF, et al.

    British journal of haematology 2019; (185(3)):549-562 doi:10.1111/bjh.15813.

    PMID: 30828796
  5. 5

    Low-dose prednisone and immunoglobulin G treatment for woman at risk for neonatal alloimmune thrombocytopenia and T helper 1 immunity.

    Skariah A, Sung N, Salazar Garcia MD, et al.

    American journal of reproductive immunology (New York, N.Y. : 1989) 2017; (77(6)) doi:10.1111/aji.12649.

    PMID: 28240400
  6. 6

    A new efficient tool for non-invasive diagnosis of fetomaternal platelet antigen incompatibility.

    Ouzegdouh Mammasse Y, Chenet C, Drubay D, et al.

    British journal of haematology 2020; (190(5)):787-798 doi:10.1111/bjh.16593.

    PMID: 32266719
  7. 7

    New Horizons in Fetal and Neonatal Alloimmune Thrombocytopenia.

    Barg A, Bonstein L

    Seminars in thrombosis and hemostasis 2023; (49(4)):402-408 doi:10.1055/s-0042-1757900.

    PMID: 36368687
  8. 8

    Non-invasive fetal HPA genotyping by UMI-NGS: a robust method for antenatal diagnosis including 48 fetal DNA markers.

    Bertrand G, Levallois O, Santesteban CG, et al.

    Blood transfusion = Trasfusione del sangue 2026; (24(1)):7-18 doi:10.2450/BloodTransfus.1070.

    PMID: 40901798
  9. 9

    A Validation Approach for Determining Fetal Blood Groups Non-Invasively by High-Sensitive Next-Generation Sequencing.

    Wienzek-Lischka S, Soelter M, Froelich A, et al.

    Journal of clinical medicine 2025; (14(19)) doi:10.3390/jcm14196812.

    PMID: 41095891
  10. 10

    Non-invasive risk-assessment and bleeding prophylaxis with IVIG in pregnant women with a history of fetal and neonatal alloimmune thrombocytopenia: management to minimize adverse events.

    Wienzek-Lischka S, Sawazki A, Ehrhardt H, et al.

    Archives of gynecology and obstetrics 2020; (302(2)):355-363 doi:10.1007/s00404-020-05618-y.

    PMID: 32495019
  11. 11

    Fetal and Neonatal Alloimmune Thrombocytopenia: Management and Outcome of a Large International Retrospective Cohort.

    Kamphuis MM, Tiller H, van den Akker ES, et al.

    Fetal diagnosis and therapy 2017; (41(4)):251-257 doi:10.1159/000448753.

    PMID: 27728915
  12. 12

    Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies.

    Winkelhorst D, Oepkes D, Lopriore E

    Expert review of hematology 2017; (10(8)):729-737 doi:10.1080/17474086.2017.1346471.

    PMID: 28644735
  13. 13

    Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia.

    de Vos TW, Winkelhorst D, de Haas M, et al.

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2020; (59(1)):102704 doi:10.1016/j.transci.2019.102704.

    PMID: 31974030
  14. 14

    Pregnant Women at Low Risk of Having a Child with Fetal and Neonatal Alloimmune Thrombocytopenia Do Not Require Treatment with Intravenous Immunoglobulin.

    Kjeldsen-Kragh J, Bein G, Tiller H

    Journal of clinical medicine 2023; (12(17)) doi:10.3390/jcm12175492.

    PMID: 37685558
  15. 15

    Fetal and neonatal alloimmune thrombocytopenia - The Norwegian management model.

    Tiller H, Ahlen MT, Akkök ÇA, Husebekk A

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2020; (59(1)):102711 doi:10.1016/j.transci.2019.102711.

    PMID: 31911047

This page provides educational information on managing FNAIT in future pregnancies. Always consult a Maternal-Fetal Medicine specialist to determine the safest personalized care plan for you and your baby.

Stay up to date

Get notified when new research about Fetal and neonatal alloimmune thrombocytopenia is published.

No spam. Unsubscribe anytime.